Financials · OFIX

Orthofix Medical Inc. (OFIX) financials

For the twelve months ended Jun 30, 2026, Orthofix Medical Inc. reported $833.19M of revenue and -$61.72M of net income.

Revenue, TTM
$833.19M
Revenue growth, YoY
+3.0%
Net income, TTM
-$61.72M
Net margin
-7.4%
Free cash flow, TTM
-$27.82M
EPS, diluted, TTM
-$1.53
Cash
$103.81M
Total debt
$221.59M
P/S
0.38
Market cap
$320.6M
Annual revenue$822.31M
FY2016FY2025
Annual net income-$92.19M
FY2016FY2025
Annual free cash flow-$1.28M
FY2016FY2025

OFIX revenue and earnings growth

OFIX revenueQ2 2026$210.93M

Quarter YoY
+3.8%
QoQ
+7.2%
FY YoY
+2.9%
5Y CAGR
+15.1%
10Y CAGR
+7.6%

OFIX revenue was $210.93M in fiscal Q2 2026 (ended Jun 30, 2026), up 3.8% from a year earlier and up 7.2% from the prior quarter. For the full fiscal 2025 it was $822.31M, up 2.9% from fiscal 2024. Compound annual growth was +15.1% over 5 years and +7.6% over 10 years. It rose in 8 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

OFIX net incomeQ2 2026-$15.80M

OFIX net income was -$15.80M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$14.08M a year earlier. For the full fiscal 2025 it was -$92.19M, compared with -$126.00M in fiscal 2024.

OFIX EPSQ2 2026-$0.39

OFIX diluted EPS was -$0.39 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.36 a year earlier. For the full fiscal 2025 it was -$2.33, compared with -$3.30 in fiscal 2024.

OFIX free cash flowQ2 2026-$18.87M

OFIX free cash flow was -$18.87M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $4.53M a year earlier. For the full fiscal 2025 it was -$1.28M, compared with -$9.09M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue$822.31M$799.49M$746.64M$460.71M$464.48M$406.56M$459.95M$453.04M$433.82M$409.79M
Cost of revenue$256.30M$253.61M$260.37M$123.54M$114.91M$101.89M$100.61M$96.63M$93.04M$87.85M
Gross profit$566.02M$545.88M$486.27M$337.17M$349.56M$304.67M$359.35M$356.41M$340.79M$321.94M
Research and development$65.85M$73.64M$80.23M$49.06M$49.62M$39.06M$34.64M$33.22M$29.70M$28.80M
Selling, general and admin$554.33M$532.52M$530.39M$308.78M$69.35M$67.95M$85.61M$83.25M$71.91M$76.41M
Operating income-$81.43M-$84.62M-$139.11M-$13.27M-$8.31M-$6.27M-$18.78M$30.09M$40.81M$21.07M
Pre-tax income-$90.81M-$123.88M-$148.68M-$17.71M-$13.49M-$368.0K-$27.05M$22.89M$36.39M$19.02M
Income tax$1.38M$2.12M$2.72M$2.04M$24.88M-$2.88M$1.41M$9.07M$29.10M$15.53M
Net income-$92.19M-$126.00M-$151.40M-$19.75M-$38.38M$2.52M-$28.46M$13.81M$6.22M$3.06M
EPS, basic-$2.33-$3.30-$4.12-$0.98-$1.95$0.13-$1.51$0.73$0.34$0.17
EPS, diluted-$2.33-$3.30-$4.12-$0.98-$1.95$0.13-$1.51$0.72$0.34$0.17
Diluted shares39.6M38.1M36.7M20.1M19.7M19.4M18.9M18.9M18.5M18.5M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$82.03M$83.24M$33.11M$50.70M$87.85M$96.29M$69.72M$69.62M$81.16M$39.57M
Receivables$135.75M$134.71M$128.10M$82.86M$78.56M$72.42M$86.81M$77.75M$63.44M$57.85M
Inventory$172.32M$189.45M$222.17M$100.15M$82.97M$84.64M$82.40M$76.85M$81.33M$63.35M
Current assets$416.85M$433.29M$420.44M$255.99M$269.52M$270.38M$260.55M$244.64M$251.80M$194.37M
Goodwill$194.93M$194.93M$194.93M$71.32M$71.32M$84.02M$71.18M$72.40M$53.56M$53.56M
Total assets$850.65M$893.29M$925.32M$458.63M$476.62M$525.86M$495.62M$466.64M$405.35M$372.10M
Current liabilities$170.48M$168.63M$165.22M$83.62M$105.83M$103.90M$84.88M$85.91M$79.41M$83.44M
Short-term debt$0$0$1.25M-------
Long-term debt$157.39M$157.01M$93.11M-------
Total debt$157.39M$157.01M$94.36M-------
Total liabilities$400.61M$390.17M$326.58M$121.77M$139.69M$169.00M$167.99M$131.24M$108.75M$108.63M
Shareholders' equity$450.04M$503.12M$598.73M$336.86M$336.93M$356.86M$327.63M$335.40M$296.61M$263.48M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow$33.35M$25.79M-$45.75M-$11.54M$18.48M$74.27M$32.03M$49.92M$38.97M$59.08M
Capital expenditures$34.63M$34.88M$62.05M$23.16M$17.79M$15.48M$19.00M$13.59M$14.66M$16.43M
Free cash flow-$1.28M-$9.09M-$107.80M-$34.70M$690.0K$58.79M$13.04M$36.33M$24.31M$42.64M
Investing cash flow-$34.60M-$27.58M-$33.13M-$24.53M-$23.01M-$52.33M-$22.92M-$61.00M-$16.47M-$21.95M
Financing cash flow-$786.0K$50.71M$65.32M-$78.0K-$3.62M$3.25M-$10.69M$2.99M$3.54M-$46.11M
Share repurchases---------$63.42M
Stock-based compensation$28.69M$32.45M$35.71M$18.44M$15.43M$16.21M$21.54M$18.93M$12.56M$15.97M
Depreciation and amortization$77.32M$60.06M$53.06M$29.02M$29.60M$30.55M$24.70M$18.66M$20.12M$20.84M

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY2.9%7.1%62.1%-0.8%14.2%-11.6%1.5%4.4%5.9%3.4%
Net income growth, YoY-------121.9%103.6%-
EPS growth, YoY-------111.8%100.0%-
Gross margin68.8%68.3%65.1%73.2%75.3%74.9%78.1%78.7%78.6%78.6%
Operating margin-9.9%-10.6%-18.6%-2.9%-1.8%-1.5%-4.1%6.6%9.4%5.1%
Net margin-11.2%-15.8%-20.3%-4.3%-8.3%0.6%-6.2%3.0%1.4%0.7%
Free cash flow margin-0.2%-1.1%-14.4%-7.5%0.1%14.5%2.8%8.0%5.6%10.4%
Return on equity-20.5%-25.0%-25.3%-5.9%-11.4%0.7%-8.7%4.1%2.1%1.2%
Return on assets-10.8%-14.1%-16.4%-4.3%-8.1%0.5%-5.7%3.0%1.5%0.8%
Current ratio2.452.572.543.062.552.603.072.853.172.33
Debt to equity0.350.310.16-------

Source: XBRL data Orthofix Medical Inc. files with the SEC, latest filing dated Aug 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

OFIX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
OFIX$833.19M+3.0%-$61.72M-7.4%$320.6M
SYK$26.30B+7.9%$3.62B13.8%$124.05B
MMM$25.25B+1.7%$3.54B14.0%$95.67B
BSX$21.07B+8.9%$3.50B16.6%$61.96B
BDX$23.25B+17.4%$941.00M4.0%$57.71B
MDLN$30.68B-$683.00M2.2%$52.13B
RMD$5.73B+9.0%$1.59B27.8%$33.10B
DXCM$5.10B+13.0%$991.00M19.4%$29.62B
WST$3.40B+12.6%$638.90M18.8%$27.85B

OFIX FAQ

9 questions
  • What is OFIX revenue?
    Orthofix Medical Inc. (OFIX) reported $833.19M of revenue for the twelve months ended Jun 30, 2026. That is up 3.0% from the year before. Revenue for fiscal 2025 was $822.31M.
  • Is OFIX profitable?
    No. Orthofix Medical Inc. reported a net loss of $61.72M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does OFIX have?
    Orthofix Medical Inc. reported $103.81M in cash and cash equivalents and $221.59M of debt on its most recent balance sheet in SEC filings.
  • How fast is OFIX revenue growing?
    Orthofix Medical Inc.'s revenue changed +2.9% in fiscal 2025, to $822.31M. Its compound annual growth rate was +15.1% over 5 years and +7.6% over 10 years.
  • What is OFIX gross margin?
    Orthofix Medical Inc.'s gross profit was $594.12M on $833.19M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 71.3%.
  • What is OFIX free cash flow?
    Orthofix Medical Inc. generated -$27.82M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of $16.27M less capital expenditures.
  • What is OFIX earnings per share?
    Diluted earnings per share were -$1.53 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did OFIX last report financial results?
    The latest statements here come from Orthofix Medical Inc.'s 10-Q filed on Aug 5, 2026, covering the period ended Jun 30, 2026.
  • Where does this OFIX financial data come from?
    Quantisnow builds these statements from the structured XBRL data Orthofix Medical Inc. files with the SEC. It is provided for information only and is not investment advice.